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Abstract (250 words) 
Background and aims:  
Hepatitis delta virus (HDV) infection accelerates the progression of hepatitis B virus (HBV)-
related liver disease. We assessed the epidemiological characteristics of HDV infection in the 
nationwide Swiss HIV Cohort Study and evaluated its impact on clinical outcomes. 
Methods: 
All HIV-infected patients with a positive HBsAg test were considered and tested for anti-HDV 
antibodies. HDV amplification and sequencing were performed in anti-HDV-positive patients. 
Demographic and clinical characteristics at initiation of antiretroviral therapy, as well as 
causes of death were compared between HDV-positive and HDV-negative individuals using 
descriptive statistics. Kaplan-Meier and multivariable Cox regression analyses were used to 
evaluate the association between HDV infection and overall mortality, liver-related mortality 
as well as incidence of hepatocellular carcinoma (HCC).  
Results: Of 818 patients with a positive HBsAg, 771 (94%) had a stored serum sample 
available and were included. The prevalence of HDV infection was 15.4% (119/771, 95% 
confidence interval (CI): 12.9-18.0) and the proportion of HDV-positive patients with HDV 
replication 62.9% (73/116). HDV-infected patients were more likely to be persons who inject 
drugs (PWID) (60.6% vs. 9.1%) and to have a positive HCV serology (73.1% vs. 17.8%) 
compared to HDV-uninfected ones. HDV infection was strongly associated with overall death 
(adjusted hazard ratio 2.33, 95% CI 1.41-3.84), liver-related death (7.71, 3.13-18.97) and 
with the occurrence of HCC (9.30, 3.03-28.61). Results were similar when PWID or HCV-
coinfected patients were excluded from the analyses. 
Conclusions: The prevalence of HDV in HBsAg-positive patients in the SHCS is high and 
HDV infection is independently associated with mortality and liver-related events, including 
HCC. 
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Introduction: 
Worldwide 15-20 million people are infected with hepatitis delta virus (HDV), with the highest 
prevalence reported in regions endemic for hepatitis B virus (HBV) infection such as Eastern 
and Mediterranean Europe, sub-Saharan Africa (SSA) and parts of Asia 1,2. It is estimated 
that 5- 20% of HBV-infected individuals have serological evidence of exposure to HDV 3. 
However, data on the prevalence of HDV in HIV/HBV-coinfected patients are scarce. Of a 
selected sample of 422 hepatitis B surface antigen (HBsAg) carriers in the EuroSIDA 
collaboration, 61 (14%) were coinfected with HDV 4. The prevalence of anti-HDV antibodies 
seems even higher in HIV/HBV-coinfected patients from SSA, reaching 25% in Guinea-
Bissau 5. Although the prevalence of HDV infection seems to decrease in some regions, 
most probably due to HBV preventive measures 6, this is not the case in Northern Europe, 
where most cases are now diagnosed in young migrants from endemic regions 2.  
HDV accelerates the course of HBV-related liver disease, including the progression to liver 
cirrhosis, hepatic decompensation and possibly hepatocellular carcinoma (HCC) 7,8. In HIV-
infected patients, the presence of HDV-coinfection has been associated with a higher 
incidence of hepatic flares and decompensation as well as an increased mortality 9,10. 
However, most studies assessing the impact of HDV on long-term outcomes in HIV/HBV-
coinfected individuals were limited by small sample sizes, highly selected study populations, 
short follow-up periods or by a retrospective design. Although most HIV/HBV/HDV-coinfected 
patients now experience HBV virological suppression on tenofovir disoproxil  fumarate 
(TDF)-containing antiretroviral therapy (ART), its impact on HDV replication remains 
controversial 11,12. Thus, it’s impact on mortality and liver-related complications needs to be 
evaluated in prospective studies with long-term follow-up.   
In this study, we aimed to describe the main epidemiological characteristics of HDV infection 
and to evaluate its impact on clinical outcomes in the Swiss HIV Cohort Study (SHCS) 13.The 
systematic ascertainment of death causes and liver-related complications in the SHCS 
allowed us to perform a detailed assessment of liver-related outcomes in a nationwide 
representative cohort of HIV/HBV-coinfected individuals. 
 
Patients and methods 
Swiss HIV Cohort Study (SHCS): 
The SHCS (www.shcs.ch) is a prospective cohort study with ongoing enrollment of HIV-
infected adults in Switzerland since 198813. It includes 73% of all diagnosed HIV-infections in 
Switzerland14. Representativeness has remained stable over the years. Detailed information 
on demographics, mode of HIV acquisition, risk behavior, clinical events, coinfections, and 
treatment is collected using a standard protocol at registration and at intervals of 6 months. 
  
5 
 
Plasma samples are collected every 6-12 months in all study participants. Local ethical 
committees of all participating study sites have approved the study and written consent has 
been obtained from all participants. 
 
Inclusion criteria, definitions and outcomes: 
All HIV-infected adults with a positive HBsAg test between January 1988 and December 
2014 were considered. We performed a screening HDV serology in all patients without 
information on HDV infection in the database and excluded patients without available stored 
samples from our analysis. This measurement was performed on the stored serum samples 
drawn closest to the diagnosis of HBV infection. In all individuals with a positive HDV 
serology, we quantitatively assessed HDV RNA in the same sample or the first available 
sample after the positive HDV serology. To rule out false-positive HDV screening results, we 
performed a second anti-HDV serology in all patients with negative HDV RNA. Patients with 
false-positive HDV screening results were re-classified as HDV-negative.   
Our primary outcome was overall mortality after the initiation of ART. Individual follow-up 
started at initiation of ART and ended on the date of death, loss to follow-up or database 
closure (31.12.2014), whichever happened first. The secondary outcomes were: 
development of i) HCC and ii) liver-related death, which included death from chronic viral 
hepatitis, cirrhosis, HCC, acute liver failure and variceal bleeding, as coded in ICD-10. In the 
SHCS, data on causes of death are collected on standardized case-report forms, using 
reports from medical hospitalizations to inform and validate the diagnosis 
(http://shcs.ch/userfiles/file/documents/CODE.pdf). Patients who did not initiate ART, defined 
as a combination of at least three antiretroviral drugs, were excluded from the longitudinal 
analyses. 
 
Laboratory analyses: 
The ETI-AB-DELTA-2TM (Diasorin, Saluggia, Italy), a competition ELISA test, was used to 
screen for anti-HDV antibodies in all HBsAg-positive individuals. All analyses were performed 
according to the manufacturer’s instructions and the results were considered positive when 
the optical density (OD) was <0.9. For HDV amplification, total nucleic acids were purified 
from 200µl plasma (Qiagen EZ1 DSP kit) and cDNA (High Capacity cDNA Reverse 
Transcription Kit, Applied BiosystemsTM) was subjected to real-time polymerase chain 
reaction (PCR) according to Ferns et al., with minor modifications 15. The detection limit of 
HDV real-time PCR was 1000 genome equivalents per ml of plasma. The HDV genotype 
was assessed by sequencing and phylogenetic analysis of a 260-base-pair cDNA fragment 
encompassing the 3’ end of the hepatitis D antigen coding region. A second serological 
ELISA test with a sensitivity and specificity >98% (HDV-AbTMkit, Diapro, Milan, Italy, 
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performed with an ETI-Max [DiaSorin] platform) was used to confirm the anti-HDV screening 
results from all samples with a positive screening serology but negative HDV RNA. A result 
was considered negative when the ratio (threshold/OD) was <0.9. Plasma samples were 
diluted 1:1 with plasma and HBV was quantified with the COBAS® TaqMan® HBV Test v2.0 
on the COBAS AmpliPrep/TaqMan48 system (Roche Diagnostics International AG, 
Rotkreuz, Switzerland) according to the manufacturer’s protocol. HBV Genotyping was 
performed by PCR Amplification, Sanger sequencing and subsequent in silico analysis by 
the geno2pheno tool (http://hbv.geno2pheno.org/index.php) as described by Hirzel et al16. 
The quantitative determination of HBsAg was analyzed with a fully automated 
chemiluminescent microparticle immunoassay (Architect, Abbott Diagnostics,USA). The 
Architect HBs Ag Assay has a sensitivity of ≤  0.05 IU/ml. 
 
Statistical analyses: 
The prevalence of HDV infection among all HIV/HBV-coinfected individuals was estimated 
after the re-classification of false-positive results and given with a 95% confidence interval 
(CI). Demographic and clinical characteristics at initiation of ART were described using 
absolute numbers and proportions, or medians and interquartile ranges (IQR), and compared 
between HIV/HBV- and HIV/HBV/HDV-coinfected patients using Chi-square, Fisher’s exact 
or Mann-Whitney test, where appropriate. Kaplan-Meier analyses and the rank-sum tests 
were used to compare overall and liver-related mortality as well as HCC-free survival 
between study groups. The association between HDV infection and the main outcomes was 
further explored using multivariable Cox regression analyses adjusted for age, sex, CD4 cell 
count, stage of HIV infection, most likely source of HIV transmission and hepatitis C virus 
(HCV) coinfection. 
We performed several sensitivity analyses. We repeated the main analysis comparing 
HIV/HBV/HDV-RNA negative and HIV/HBV/HDV-RNA positive patients.  We evaluated the 
association between HDV infection and the main outcomes after the exclusion of persons 
who inject drugs (PWID) and patients with a positive HCV serology. As these two categories 
of patients are more likely to have multiple comorbidities and to die during follow-up, their 
over-representation in the HDV-positive group could have had an important impact on our 
results. As longitudinal data on HBV replication were lacking, we used TDF treatment as a 
proxy for HBV suppression, and evaluated the association between HDV infection and the 
main outcomes after the exclusion of persons who had never been treated with TDF.  All 
statistical analyses were performed using Stata Version 13.1. (StataCorp 2012, Stata 
Statistical Software, College Station, TX, USA). 
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Results: 
HDV prevalence 
Of 818 patients with a positive HBsAg, 771 (94%) had an HDV serology performed, either 
during routine care (422/771) or from a stored serum sample (349/771) (Fig. 1). Overall, 139 
patients (18%) had a positive HDV screening serology, of which 122 had a sample available 
for amplification. Seventy-three patients (59%) examined by PCR had a detectable HDV 
RNA. After the re-classification of 20 patients with a positive HDV screening test but negative 
viral load and negative confirmation anti-HDV tests, the prevalence of HDV infection was 
15.4% (119/771, 95% CI: 12.9-18.0) and the proportion of HDV-positive patients with HDV 
replication 62.9% (73/116). Of 70 patients with available results from HDV sequencing, 66 
(94.3%) were infected with genotype 1 and four (5.7%) with genotype 5. 
 
Characteristics of HDV infection 
Fifteen (12.6%) patients from the HDV-positive group and 29 (4.5%) from the HDV-negative 
group never started ART during follow-up and  were excluded from the longitudinal analyses. 
Table 1 summarizes the main characteristics of the study population at ART initiation, by 
HDV-infection status. Whereas age and sex distribution were similar across both groups, 
HDV-positive individuals were more likely to be PWID (60.6% vs. 9.1%) and to have a 
positive HCV serology (73.1% vs. 17.8%) compared to HDV-uninfected ones. Among 
individuals with a positive HCV serology, only 15/76 (20%) in the HDV-positive group had 
detectable HCV RNA compared to 67/111 (60%) in the HDV-uninfected group. In 
HIV/HBV/HDV-coinfected patients with replicating HDV, HCV-RNA was suppressed in 90% 
of patients. Of the anti-HDV-positive patients, 34/74 (46%) had suppressed HBV DNA at the 
time of measurement and 75% of them were under an ART with at least one drug active 
against HBV. Compared to HDV-negative patients, patients coinfected with HDV were more 
likely to have genotype D HBV infection. HDV-RNA-positive patients were more likely to have 
a replicating HBV-DNA and had higher quantitative HBsAg than HDV-RNA-negative patients 
(Table S3).  The median CD4 cell count as well as the relative CD4 value were lower in 
HDV-infected (180 vs. 248 cells/µl and 19% vs. 24%) and the median ALT level higher (61 
vs. 33 IU/L) than in HDV-negative patients. 
 
Mortality and liver related outcomes 
Thirty-six (34.6%) HDV-infected patients and 96 (15.4%) HDV-uninfected individuals died 
during 6,718 patient-years (py) of follow-up. Median follow-up was 8.71 years (interquartile 
range [IQR]: 5.01-13.78) in the HDV-positive and 9.75 years (IQR: 4.71-15.27) in the HDV-
negative group. Causes of death by HDV status are summarized in Fig. 2. One half of the 
deaths were liver-related (18/36) in HDV-infected patients (8 deaths from HCC and 10 from 
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decompensated liver disease), compared to 24.0% (23/96) in HDV-uninfected individuals (12 
deaths from HCC and 11 from decompensated  liver disease). Overall mortality was higher in 
HDV-infected patients (3.62 deaths per 100 py, 95% CI 2.59-5.07) compared to uninfected 
ones (1.49 per 100 py, 95% CI 1.20-1.84). Kaplan-Meier cumulative survival probability was 
significantly higher among HDV-negative patients (p<0.001, Fig. 3A). The cumulative 
probability of liver-related deaths as well as HCC were significantly higher in HDV-positive 
patients compared to HDV-negative ones (both p<0.001; Fig. 3B and 3C).  
In multivariable analyses, HDV infection was strongly associated with overall death (adjusted 
hazard ratio [aHR] 2.33, 95% CI 1.41-3.84) ), with liver-related mortality (aHR 7.71, 95% CI 
3.13-18.97), and with the occurrence of HCC (aHR 9.30, 95% CI 3.03-28.61, Fig. 4 and 
Table S1). The risk for non-liver related deaths did not differ significantly between HDV-
positive and –negative patients (aHR 1.36, 95% CI 0.72-2.57).  In analyses comparing HDV-
RNA-negative and HDV-RNA-positive patients, we found that the cumulative probability for 
overall death, liver-related death and HCC were significantly higher in HDV-RNA-positive 
patients (Table S2, Fig. 3, panels D-F). In multivariable analyses, HDV replication was 
strongly associated with overall death (adjusted hazard ratio [aHR] 7.14, 95% CI 1.60-31.85), 
liver-related mortality and the occurrence of HCC. There were no liver-related deaths and no 
HCC in patients that were HDV-RNA-negative. Results were similar when PWID or HCV-
infected individuals were excluded from the analyses (Fig. 4). In analyses stratified by viral 
hepatitis coinfection sub-group (HIV/HBV, HIV/HBV/HDV, HIV/HBV/HCV and 
HIV/HBV/HDV/HCV), overall survival was lowest in the two groups of HDV-infected 
individuals, independently of anti-HCV antibody status or replicating HCV infection (Fig. S2 
and S3). In analyses restricted to patients who had received TDF (77%), the point estimate 
of the association between HDV infection and overall death remained similar (aHR 2.03, 95% 
CI 0.80-5.15).  
 
Discussion: 
The prevalence of HDV infection was high among HIV/HBV-coinfected individuals in 
Switzerland: 15% were antibody-positive and 63% of them had detectable viral replication. 
Over nine years of individual follow-up on ART, HDV-infected patients were twice as likely to 
die as HDV-uninfected  ones. The excess mortality in HDV-positive patients was driven by 
liver related deaths: HDV-positive individuals were eight times more likely to die from liver 
disease and  nine times more likely to develop an HCC compared to HDV-negative patients. 
These associations were robust, remaining similar in all sensitivity analyses. 
 
The prevalence of HDV infection in our cohort was similar to the findings from the EuroSIDA 
collaboration but slightly higher than the estimate reported in cohort studies from France and 
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North America17,18. As false-positive HDV screening results seem to be frequent in the setting 
of HIV-infection19, we performed a confirmatory serology in all patients with a negative HDV 
RNA in order to strengthen our HDV prevalence estimate. In our study, 14% of positive HDV 
screening tests were false-positive. After the exclusion of these patients, 63% of HDV-
positive patients had a detectable HDV viral load, which was lower than the proportion found 
in the EuroSIDA study4. Although the main reason for this difference remains unclear, the 
unselected nature of our study population, in which all patients were screened for HBV and 
HDV infection independently of clinical manifestations or laboratory abnormalities, might 
have played an important role. HDV-infected individuals were predominantly PWID of 
Western European origin, which explains the high proportion of HDV genotype 1 found in our 
cohort. As all remaining patients (6%) were HDV genotype 5-infected migrants from sub-
Saharan Africa diagnosed during the last five years, our results suggest a changing pattern 
in HDV epidemiology in Switzerland2,20,21.  Injection drug use being the most probable route 
of HDV transmission for the majority of patients included in our study, HCV infection was also 
present in many of them. The complex interplay between HBV, HCV and HDV has been 
described in several previous reports which generally showed HDV to be the dominant virus, 
often leading to the suppression of HBV as well as HCV17,22,23. In line with these findings, 
only 20% of HIV/HBV/HDV-coinfected patients and 10% of HIV/HBV/HDV-coinfected 
patients with replicating HDV in our cohort had a replicating HCV infection compared to 60% 
of HDV-negative individuals. HCV-coinfection had  no impact on overall survival in our study. 
Almost one half of  HDV-positive patients had a suppressed HBV-viremia. Those with a 
replicating HDV were more likely to also have a replicating HBV as well as higher HBsAg 
titers. 
 
HDV-positive individuals were 2.3 times more likely to die during follow-up on ART than 
uninfected ones. A detailed analysis of causes of death showed  that this finding was driven 
by the excess liver-related mortality seen in HDV-positive individuals: 50% of HDV-positive 
patients died of liver disease, resulting in an 8-fold  risk increase compared to HDV-negative 
patients. The impact of HDV on overall and liver-related mortality was further demonstrated 
by the similar estimates obtained after the exclusion of HCV-infected patients and in 
analyses limited to patients with optimal HBV-therapy. In a case-control study among HIV-
infected patients in Taiwan, Sheng et al. found that HBV/HDV-coinfected individuals were 
five times more likely to die than HBV-infected  ones 10. More recently, Fernandez-Montero et 
al. confirmed this finding and described an increase in liver-related mortality in HDV-positive 
individuals comparable to the estimate of the present study9. In our study the hazard of 
death, liver-related death and HCC was mainly driven by HDV-RNA-positive patients. 
However, due to the low number of HDV-infected patients included in previous studies of 
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HIV-positive individuals, data on the impact of HDV replication on liver-related outcomes and 
mortality are scarce.  
 
HCC was diagnosed in 23 patients of which 20 died during the study period. HDV-positive 
individuals were 9 times more likely to develop HCC as compared to HDV-uninfected HBV 
positive persons. Chronic HBV infection is the single most important risk factor of HCC 
worldwide24-26, and this risk has been shown to correlate with HBV replication27. However, the 
impact of HDV on liver carcinogenesis and its contribution to global HCC epidemiology 
remains unclear. In cirrhotic HBV-infected patients, Fattovich et al. found a 3-fold increase in 
HCC incidence among HDV-infected patients, whereas similar rates of HCC were found in 
HBV- and HBV/HDV-infected patients in a retrospective study from London.20,28. In Italy, 
Romeo et al. showed that persistent HDV replication was strongly associated with the 
development of HCC but no HIV-infected individuals were included8.  To our knowledge, our 
study is the first to be powered to detect a difference in HCC incidence between HDV-
infected and -uninfected  HIV-positive individuals and calls for other cohorts to confirm these 
results.  
 
We studied the impact of HDV infection on clinical outcomes in one of the largest studies of 
HIV/HBV-coinfected patients to date. Long individual follow-up time as well as the systematic 
ascertainment of death and liver-related complications allowed us to provide robust 
estimates of liver-related mortality and HCC. Only very few patients were excluded from our 
analyses: HDV serology results were available for 94% of HBsAg-positive patients and 88% 
of HDV-positive individuals had an assessment of viral replication. Furthermore, the 
probability of false-positive results was substantially reduced by using confirmatory serologic 
tests. Unfortunately, information on HBV viral load and genotypes was only available for a 
limited number of patients, precluding its use in the main analyses. As there is a clear link 
between HBV viral load and liver-related outcomes such as HCC, our analyses do not 
provide the full picture of risk factors for liver disease. However, analyses which were 
restricted to patients on TDF, a good proxy for HBV suppression, showed results which were 
comparable to the main analyses. Although Su et al. showed worse outcomes in HBV 
genotype C than B in Taiwan, our results are unlikely to be affected by the HBV genotype 
distribution, as only 5% or our patients were of Asian origin29. The large difference in the 
proportion of PWID and HCV infections across both study groups was another limitation of 
our study, as these characteristics are known risk factors for mortality and liver-related 
morbidity. Again, sensitivity analyses showed that the association between HDV infection 
and the main outcomes were independent of these two cofactors. Finally, we only had 
information on HDV viral replication at one time-point for each patient and, as a 
  
11 
 
consequence, might have misclassified patients as HDV RNA-negative despite potential 
subsequently detectable replication.  
 
In conclusion, we found a high prevalence of hepatitis delta in HIV/HBV-coinfected 
individuals in Switzerland. The strong association between HDV infection and mortality as 
well as liver-related events, including HCC, highlights the importance of HDV screening of all 
HIV/HBV-coinfected patients. Our results emphasize the need for systematic screening for 
HDV infection,  the close monitoring of HDV-infected patients and underline the importance 
of developing and evaluating new treatments for chronic hepatitis D. As potent treatment 
options for HDV are still lacking, preventing infections through the implementation of efficient 
HBV vaccination programs remains a cornerstone of the prevention of HDV infection. In 
persons with HDV-coinfection  and ESLD or HCC, liver transplantation  from an HBsAg-
negative donor should be considered. 
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Fig. 1: Patient flowchart 
 
Abbreviations:HDV, hepatitis D virus; PCR, polymerase chain reaction; ART, antiretroviral therapy 
 
 
Table 1: Demographic and clinical characteristics of patients at ART initiation, by HDV status 
 
Abbreviations: ART, antiretroviral therapy;  HDV, hepatitis D virus; HBV, hepatitis B virus; IQR, interquartile range; 
HIV, human immunodeficiency virus; MSM, men who have sex with men; PWID, people who inject drugs; HET, 
heterosexual; CDC: Centers for Diseases Control ; eGFR, estimated glomerular filtration rate; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; Ab: antibody; APRI: AST-to-platelet 
ratio index  
*eGFR: calculated with the CKD-EPI formula 
**Anemia defined as follows: Mild: hemoglobin <13 G/L in males and<12G/L in females. Moderate-severe: 
hemoglobin <11 G/L in males and<10G/L in females 
***ACTG (AIDS Clinical Trials Group) Grade 1-4  
 
 
Fig. 2: Main cause of death, by hepatitis D virus (HDV) status 
 
Absolute numbers of death are shown at the bottom of the bars 
Abbreviations: HIV, human immunodeficiency virus; CVD  cardiovascular disease; HDV, hepatitis delta virus 
 
 
Fig. 3: Kaplan–Meier survival analyses by hepatitis D virus (HDV) serological and replication 
status for overall survival (A, D), liver-related mortality (B, E) and hepatocellular carcinoma 
(HCC) free survival (C, F) 
 
Abbreviations: ART, antiretroviral therapy; HDV, hepatitis D virus; CI, coinfidence interval; HCC, hepatocellular 
carcinoma 
 
 
Fig. 4: Forest plot of hazard ratios for the main outcomes (adjusted for age, sex, CD4 
cell count, stage of HIV infection, most likely source of HIV transmission and hepatitis C virus 
(HCV) coinfection) 
 
Abbreviations: aHR, adjusted haazrd ratio; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; PWID, people 
who inject drugs 
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Hepatitis delta virus (HDV) infection accelerates the progression of hepatitis B virus (HBV)-
related liver disease. In a nationwide cohort of HIV-infected individuals in Switzerland, 15% 
of HBV-coinfected patients had antibodies to HDV infection, of which a majority had active 
HDV replication. HDV-infected individuals were 2.5 times more likely to die, 8 times more 
likely to die from a liver-related cause and 9 times more likely to develop liver cancer 
compared to HDV-uninfected ones. Our results emphasize the need for prevention programs 
(including HBV vaccination), the systematic screening of at risk populations as well as close 
monitoring, and underline the importance of developing new treatments for chronic HDV 
infection.  
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Table 1: Demographic and clinical characteristics of patients at ART initiation, by HDV status 
 
Characteristics HDV-positive 
(N=104) 
HDV-negative 
(N=623) 
P 
Age, median (IQR) 34 (29-37) 36 (30-43) <0.001 
Male sex (%) 79 (76.0) 487 (78.2) 0.25 
Region of origin (%) 
  Northwestern Europe 
  Central and Eastern Europe 
  Southern Europe (Mediterranean) 
  Sub-Saharan Africa 
  Southeast Asia 
  Other 
 
74 (71.1) 
2 (1.9) 
14 (13.5) 
13 (12.5) 
1 (1) 
0 (0) 
 
344 (55.2) 
18 (2.9) 
64 (10.3) 
131(21) 
38 (6.1) 
28 (4.5) 
0.01 
Education level (%) 
  No or low  
  Medium 
  High 
  No information 
 
49 (47.1) 
35 (33.6) 
7 (6.7) 
13 (12.5) 
 
187 (30) 
255 (40.9) 
150 (24.1) 
31 (5) 
<0.001 
HIV transmission group (%) 
  MSM 
  PWID 
  HET 
  Other 
 
10 (9.6) 
63 (60.6) 
17 (16.3) 
14 (13.5) 
 
300 (48.1) 
57 (9.1) 
217 (34.8) 
49 (7.9) 
<0.001 
 
 
Median HIV RNA in log cp/ml (IQR) 4.6 (3.2-5.1) 4.7 (3.3-5.2) 0.70 
CDC stage C (%) 34 (32.7) 191 (30.7) 0.17 
Median CD4 count in cells/µl (IQR) 180 (96-314) 248 (120-358) 0.03 
CD4 cell count category in cells/µl (%) 
  1-200 
  201-350 
  >350 
 
52 (50.5) 
33 (32) 
18 (17.5) 
 
242 (40) 
201 (33.2) 
162 (26.8) 
0.07 
Median creatinine in µmol/L (IQR) 
  eGFR in ml/min (IQR)* 
71.5 (67-84) 
103 (94-123) 
75 (65-90) 
109 (93-126) 
0.68 
0.80 
Median hemoglobin in g/L (IQR) 13.8 (12.4-14.2) 14.1 (12.7-15.2) 0.11 
Anemia (%)** 
  No  
  Mild  
  Moderate-Severe  
 
72 (75.8) 
16 (16.8) 
7 (7.4) 
 
415 (76.4) 
100 (18.4) 
28 (5.2) 
0.66 
Median thrombocytes in G/L (IQR)  158 (113-212) 206 (161-246) <0.001 
Median ALT in IU/L (IQR) 61 (36-90) 33 (23-59) 0.04 
Anti-HCV positive (%) 76 (73.1) 111 (17.8) <0.001 
Abbreviations: ART, antiretroviral therapy;  HDV, hepatitis D virus; HBV, hepatitis B virus; IQR, interquartile range; 
HIV, human immunodeficiency virus; MSM, men who have sex with men; PWID, people who inject drugs; HET, 
heterosexual; CDC: Centers for Diseases Control ; eGFR, estimated glomerular filtration rate; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; Ab: antibody; APRI: AST-to-platelet 
ratio index  
*eGFR: calculated with the CKD-EPI formula 
**Anemia defined as follows: Mild: hemoglobin <13 G/L in males and<12G/L in females. Moderate-severe: 
hemoglobin <11 G/L in males and<10G/L in females 
***ACTG (AIDS Clinical Trials Group) Grade 1-4  
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